REFERENCES
- Sharma T, Antonova L. Cognitive function in schizophrenia. Deficits, functional consequences, and future treatment. Psychiatr Clin North Am 2003; 26: 25–40, [PUBMED], [INFOTRIEVE], [CSA]
- Sullivan P F, Kendler K S, Neale M C. Schizophrenia as a complex trait—evidence from a meta-analysis of twin studies. Arch Gen Psychiatry 2003; 60: 1187–92, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Straub R C, MacLean C J, O'Neill F A, et al. A potential vulnerability locus for schizophrenia on chromosome 6p24-22: evidence for genetic heterogeneity. Nat Genet 1995; l11: 287–93, [CROSSREF], [CSA]
- Blouin J L, Dombrowski B A, Nath S K, et al. Schizophrenia susceptibility loci on chromosomes 13q32 and 8p81. Nat Genet 1998; 20: 70–3, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Brzustowicz L M, Hodgkinson K A, Chow E WC, Honer W G, Bassett A S. Location of a major susceptibility locus for familial schizophrenia on chromosome 1q21-22. Science 2000; 288: 678–82, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Williams N M, Norton N, Williams H, et al. A systematic genomewide linkage study in 353 sib pairs with schizophrenia. Am J Hum Genet 2003; 73: 1355–67, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Harrison P J, Weinberger D R. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 2005; 10: 40–68, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Mattay V S, Goldberg T E. Imaging genetic influences in human brain function. Curr Opin Neurobiol 2004; 14: 239–47, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hariri A R, Weinberger D R. Imaging genomics. Br Med Bull 2003; 65: 259–70, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Gottesman I I, Shields J. Schizophrenia and genetics: a twin study vantage point. Academic, New York 1972
- Gershon E S, Goldin L R. Clinical methods in psychiatric genetics, I: robustness of genetic marker investigative strategies. Acta Psychiatr Scand 1986; 74: 113–8, [PUBMED], [INFOTRIEVE], [CSA]
- Gottesman I I, Gould T D. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 2003; 160: 636–45, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Callicott J H, Weinberger D R. Brain imaging as an approach to phenotype characterization for genetic studies of schizophrenia. Psychiatric genetics: methods and reviews, M Leboyer, F Bellivier. Humana, Totowa, NJ 2003; 227–50
- Cannon T D, van Erp T G, Huttunen M, et al. Regional gray matter, white matter, and cerebrospinal fluid distributions in schizophrenic patients, their siblings, and controls. Arch Gen Psychiatry 1998; 55: 1084–91, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Callicott J H, Egan M F, Bertolino A, et al. Hippocampal N-acetyl aspartate in unaffected siblings of patients with schizophrenia: a possible intermediate neurobiological phenotype. Biol Psychiatry, l44: 941–50, [CSA]
- Callicott J H, Egan M F, Mattay V S, et al. Abnormal fMRI response of the dorsolateral prefrontal cortex in cognitively intact siblings of patients with schizophrenia. Am J Psychiatry 2003; 160: 709–19, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Goldberg T E, Weinberger D R. Genes and the parsing of cognitive processes. Trends Neurosci 2004; 8: 325–35, [CSA]
- Pezawas L, Meyer-Lindenberg A, Drabant E M, et al. 5-HTTLRP polymorphism impacts human cingulated-amygdala interactions: a genetic susceptibility mechanism for major depression. Nat Neurosci 2005; 8: 828–34, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Venter J C, Adams M D, Myers E W, et al. The sequence of the human genome. Science 2001; 291: 1304–51, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Lander E S, Linton L M, Birren B, et al. Initial sequencing and analysis of the human genome. Nature 2001; 1409: 860–921, [CROSSREF], [CSA]
- Dougherty D D, Rauch S L, Rosenbaum J F. Essentials of neuroimaging for clinical practice. American Psychiatric Association, Washington, DC 2004
- Altshuler D, Pollara V J, Cowles C R, , An S NP, et al. map of the human genome generated by reduced representation shotgun sequencing. Nature 2000; 407: 513–6, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Sachidanandam R, Weissman D, Schmidt S C, et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 2001; 409: 928–33, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Winterer G, Weinberger D R. Genes, dopamine, and cortical signal-to-ratio in schizophrenia. Trends Neurosci 2004; 27: 683–90, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kunugi H, Vallada H P, Sham P C, et al. Catechol-o-methyltransferase polymorphisms and schizophrenia: a transmission disequilibrium study in multiply affected families. Psychiatr Genet 1997; 7: 97–101, [PUBMED], [INFOTRIEVE], [CSA]
- Li T, Sham P C, Vallada H, Xie T, et al. Preferential transmission of the high activity allele of {COMT} in schizophrenia. Psychiatr Genet 1996; 6: 131–3, [PUBMED], [INFOTRIEVE], [CSA]
- Li T, Ball D, Zhao J, et al. Family-based linkage disequilibrium mapping using SNP marker haplotypes: application to a potential locus for schizophrenia at chromosome 22q11. Mol Psychiatry 2000; 5: 77–84, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Badner J A, Gershon E S. Meta-analysis of whole-genome linkage scans of bipolar disorder and schizophrenia. Mol Psychiatry 2002; 7: 405–11, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Murray K C, Jones L A, Owen M J. High rates of schizophrenia in adults with velo-cardio-facial syndrome. Arch Gen Psychiatry 1999; 56: 940–5, [CROSSREF], [CSA]
- Karayiorgou M, Morris M A, Morrow B, et al. Schizophrenia susceptibility associated with interstitial deletions of chromosome 22q11. Proc Natl Acad Sci U S A 1995; 92: 7612–6, [PUBMED], [INFOTRIEVE], [CSA]
- Freedman M L, Reich D, Penney K L, et al. Assessing the impact of population stratification on genetic association studies. Nat Genet 2004; 36: 388–93, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Fan J B, Zhang C S, Gu N F, et al. Catechol-O-methyltransferase gene Val/Met functional polymorphism and risk of schizophrenia: a large-scale association study plus meta-analysis. Biol Psychiatry 2005; 57: 139–44, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Page G P, George V, Go R C, Page P, Allison D B. Are we there yet? Deciding when one has demonstrated specific genetic causation in complex disorders and quantitative traits. Am J Hum Genet 2003; 3: 711–9, [CROSSREF], [CSA]
- Lotta T, Vidgren J, Tilgmann C, et al. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 1995; 34: 4202–10, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Weinshilboum R M, Otterness D M, Szumlanski C L. Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu Rev Pharmacol Toxicol 1999; 39: 19–52, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Moore H, West A R, Grace A A. The regulation of forebrain dopamine transmission: relevance to the pathophysiology and psychopathology of schizophrenia. Biol Psychiatry 1999; 46: 40–55, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Karoum F, Chrapusta S J, Egan M F. 3-Methoxytyramine is the major metabolite of released dopamine in the rat frontal cortex: reassessment of the effects of antipsychotics on the dynamics of dopamine release and metabolism in the frontal cortex, nucleus accumbens, and striatum by a simple two pool model. J Neurochem 1994; 63: 972–9, [PUBMED], [INFOTRIEVE], [CSA]
- Gogos J A, Morgan M, Luine V, et al. Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc Natl Acad Sci U S A 1998; 95: 9991–6, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Egan M F, Goldberg T E, Kolachana B S, et al. Effect of {COMT} Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A 2001; l5;98: 6917–22, [CROSSREF], [CSA]
- Weickert T W, Goldberg T E, Mishara A, et al. Catechol-O-methyltransferase val108/158met genotype predicts working memory response to antipsychotic medications. Biol Psychiatry 2004; 56: 677–82, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Bertolino A, Caforio G, Blasi G, et al. Interaction of {COMT} (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am J Psychiatry 2004; 161: 1798–805, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Urenjak J, Williams S R, Gadian D G, Noble M. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci 1993; l13: 981–9, [CSA]
- Moffett J R, Namboodiri M A. Differential distribution of N-acetylaspartylglutamate and N-acetylaspartate immunoreactivities in rat forebrain. J Neurocytol 1995; 24: 409–33, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Bertonlino A, Nawroz S, Mattay V S, et al. Regionally specific pattern of neurochemical pathology in schizophrenia as assessed by multislice proton magnetic resonance spectroscopic imaging. Am J Psychiatry 1996; 153: 1554–63, [CSA]
- Bertolino A, Callicott J H, Elman I, et al. Regionally specific neuronal pathology in untreated patients with schizophrenia: a proton magnetic resonance spectroscopic imaging study. Biol Psychiatry 1998; 43: 641–8, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Callicott J H, Bertolino A, Egan M F, Mattay V S, Langheim F J, Weinberger D R. Selective relationship between prefrontal N-acetylaspartate measures and negative symptoms in schizophrenia. Am J Psychiatry 2000; 157: 1646–51, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Callicott J H, Bertolino A, Mattay V S, et al. Physiological dysfunction of the dorsolateral prefrontal cortex in schizophrenia revisited. Cereb Cortex 2000; 10: 1078–92, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Laruelle M. The role of endogenous sensitization in the pathophysiology of schizophrenia: implications from recent brain imaging studies. Brain Res Brain Res Rev 2000; 31: 371–84, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- McCarley R W, Wible C G, Frumin M, et al. MRI anatomy of schizophrenia. Biol Psychiatry 1999; 45: 1099–119, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Yamasue H, Iwanami A, Hirayasu Y, et al. Localized volume reduction in prefrontal, temporolimbic, and paralimbic regions in schizophrenia: an MRI parcellation study. Psychiatry Res 2004; 131: 195–207, [PUBMED], [INFOTRIEVE], [CSA]
- Narr K L, Thompson P M, Szeszki P, et al. Regional specificity of hippocampal volume reductions in first-episode schizophrenia. Neuroimage 2004; 21: 1563–75, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Weiss A P, Dewitt I, Goff D, Ditman T, Heckers S. Anterior and posterior hippocampal volumes in schizophrenia. Schizophr Res 2005; 73: 103–12, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Antonova E, Sharma T, Morris R, Kumari V. The relationship between brain structure and neurocognition in schizophrenia: a selective review. Schizophr Res 2004; 70: 117–45, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Nestor P G, Kubicki M, Gurrera R J, et al. Neuropsychological correlates of diffusion tensor imaging in schizophrenia. Neuropsychology 2004; 18: 629–37, [PUBMED], [INFOTRIEVE], [CSA]
- Weiss A P, Heckers S. Neuroimaging of declarative memory in schizophrenia. Scand J Psychol 2001; 42: 239–50, [PUBMED], [INFOTRIEVE], [CSA]
- Weiss A P, Zalesak M, De Witt I, Goff D, Kunkel L, Heckers S. Impaired hippocampal function during the detection of novel words in schizophrenia. Biol Psychiatry 2004; l55: 668–75, [CROSSREF], [CSA]
- Manoach D S, Gollub R L, Benson E S, et al. Schizophrenic subjects show aberrant fMRI activation of dorsolateral prefrontal cortex during working memory performance. Biol Psychiatry 2000; 48: 99–109, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Callicott J H, Egan M F, Mattay V S, et al. Abnormal fMRI response of the dorsolateral prefrontal cortex in cognitively intact siblings of patients with schizophrenia. Am J Psychiatry 2003; 160: 709–19, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Ragland J D, Gur R C, Glahn D C, et al. Frontotemporal cerebral blood flow change during executive and declarative memory tasks in schizophrenia: a positron emission tomography study. Neuropsychology 1998; 12: 399–413, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Ramsey N F, Koning H A, Welles P, Cahn W, van der Linden J A, Kahn R S. Excessive recruitment of neural systems subserving logical reasoning in schizophrenia. Brain 2002; l125(pt 8)1793–807, [CROSSREF], [CSA]
- MacDonald A W, 3rd, Carter C S. Event-related FMRI study of context processing in dorsolateral prefrontal cortex of patients with schizophrenia. J Abnorm Psychol 2003; 112: 689–97, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Honey G D, Bullmore E T, Sharma T. De-coupling of cognitive performance and cerebral functional response during working memory in schizophrenia. Schizophr Res 2002; 53: 45–56, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Weiss A P, Schacter D L, Goff D C, et al. Impaired hippocampal recruitment during normal modulation of memory performance in schizophrenia. Biol Psychiatry 2003; 53: 48–55, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Campbell C D, Ogburn E L, Lunetta K L, et al. Demonstrating stratification in a European American population. Nat Genet 2005; 37: 868–72, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Mattay V S, Goldberg T E, Fera F, et al. Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci U S A 2003; 100: 6186–91, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Ho B C, Wassink T H, O'leary D S, Sheffield V C, Anderasen N C. Catechol-O-methyl transferase Val(158)Met gene polymorphism in schizophrenia: working memory, frontal lobe MRI morphology and frontal cerebral blood flow. Mol Psychiatry 2005; 10: 287–98, [CROSSREF], [CSA]
- Goff D C, Coyle J T. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 2001; 158: 1367–77, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Tsai G, Coyle J T. Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol 2002; 42: 165–79, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Lahti A C, Weiler M A, Michaelidis T, Parwani A, Tamminga C A. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 2001; 25: 455–67, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Lahti A C, Holcomb H H, Medoff D R, Tamminga C A. Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport 1995; 6: 869–72, [PUBMED], [INFOTRIEVE], [CSA]
- Vollenweider F X, Leenders K L, Scharfetter C, et al. Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG). Eur Neuropsychopharmacol 1997; 7: 9–24, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Holcomb H H, Lahti A C, Medoff D R, Weiler M, Tamminga C A. Sequential regional cerebral blood flow brain scans using PET with H2(15)O demonstrate ketamine actions in CNS dynamically. Neuropsychopharmacology 2001; l25: 165–72, [CROSSREF], [CSA]
- Theberge J, Bartha R, Drost D J, et al. Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am J Psychiatry 2002; 159: 1944–6, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Theberge J, Al-Semann Y, Williamson P C, et al. Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. Am J Psychiatry 2003; 160: 2231–3, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Goff D C, Hennen J, Lyoo I K, et al. Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine. Biol Psychiatry 2002; 51: 493–7, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Lewis C M, Levinson D F, Wise L H, et al. Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: Schizophrenia. Am J Hum Genet 2003; 73: 34–48, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Marti S B, Cichon S, Propping P, Nöthen M. Metabotropic glutamate receptor 3 ({GRM3}) gene variation is not associated with schizophrenia or bipolar affective disorder in the German population. Am J Med Genet 2002; 114: 46–50, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Fujii Y, Shibita H, Kikuta R, et al. Positive associations of polymorphisms in the metabotropic glutamate receptor type 3 gene ({GRM3}) with schizophrenia. Psychiatr Genet 2003; 13: 71–6, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Egan M F, Straub R E, Goldberg T E, et al. Variation in {GRM3} affects cognition, prefrontal glutamate, and risk for schizophrenia. Proc Natl Acad Sci U S A 2004; l101: 12604–9, [CROSSREF], [CSA]
- Moghaddam B, Adams B W. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 1998; 281: 1349–52, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Aronica E, Gorter J A, Ijlst-Keizers H, et al. Expression and functional role of mGluR3 and mGluR5 in human astrocytes and glioma cells: opposite regulation of glutamate transporter proteins. Eur J Neurosci 2003; 17: 2106–18, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Ohnuma T, Tessler S, Arai H, Faull R L, McKenna P J, Emson P C. Gene expression of metabotropic glutamate receptor 5 and excitatory amino acid transporter 2 in the schizophrenic hippocampus. Brain Res Mol Brain Res 2000; 85: 24–31, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Chumakov I, Blumenfeld M, Guerassimenko O, et al. Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proc Natl Acad Sci U S A 2002; 99: 13675–80, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Goldberg T E, Straub R E, Callicott J H, et al. The G72/G30 gene complex and cognitive abnormalities in schizophrenia. Neuropsychopharmacology, (in press)[CSA]
- Woods B T. Is schizophrenia a progressive neurodevelopmental disorder? Toward a unitary pathogenetic mechanism. Am J Psychiatry 1998; 155: 1661–70, [PUBMED], [INFOTRIEVE], [CSA]
- McGrath J J, Feron F P, Burne T H, Mackay-Sim A, Eyles D W. The neurodevelopmental hypothesis of schizophrenia: a review of recent developments. Ann Med 2003; 35: 86–93, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Lipska B K. Using animal models to test a neurodevelopmental hypothesis of schizophrenia. J Psychiatry Neurosci 2004; 29: 282–6, [PUBMED], [INFOTRIEVE], [CSA]
- Akbarian S, Bunney W E, Jr, Potkin S G, et al. Altered distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase cells in frontal lobe of schizophrenics implies disturbances of cortical development. Arch Gen Psychiatry 1993; 50: 169–77, [PUBMED], [INFOTRIEVE], [CSA]
- Akbarian S, Vinuela A, Kim J J, Potkin S G, Bunney W E, Jr, Jones E G. Distorted distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase neurons in temporal lobe of schizophrenics implies anomalous cortical development. Arch Gen Psychiatry 1993; 50: 178–87, [PUBMED], [INFOTRIEVE], [CSA]
- Akbarian S, Kim J J, Potkin S G, Hetrick W P, Bunney W E, Jr, Jones E G. Maldistribution of interstitial neurons in prefrontal white matter of the brains of schizophrenic patients. Arch Gen Psychiatry 1996; 53: 425–36, [PUBMED], [INFOTRIEVE], [CSA]
- Mehler C, Warnke A. Structural brain abnormalities specific to childhood-onset schizophrenia identified by neuroimaging techniques. J Neural Transm 2002; 109: 219–34, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- White T, Andreasen N C, Nopoulos P, Magnotta V. Gyrification abnormalities in childhood- and adolescent-onset schizophrenia. Biol Psychiatry 2003; 54: 418–26, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Wiegand L C, Warfield S K, Levitt J J, et al. An in vivo MRI study of prefrontal cortical complexity in first-episode psychosis. Am J Psychiatry 2005; 162: 65–70, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Rapoport J L, Addington A M, Frangou S, Psych M R. The neurodevelopmental model of schizophrenia: update 2005. Mol Psychiatry, (in press)[CSA]
- St Clair D, Blackwood D, Muir W, et al. Association within a family of a balanced autosomal translocation with major mental illness. Lancet 1990; 336: 13–6, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Millar J K, Ilson-Annan J WC, Anderson S, et al. Disruption of two novel genes by a translocation co-segregating with schizophrenia. Hum Mol Genet 2000; 9: 1415–23, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Austin C P, Ky B, Ma L, Morris J A, Shughrue P J. Expression of Disrupted-in-Schizophrenia-1, a schizophrenia-associated gene, is prominent in the mouse hippocampus throughout brain development. Neuroscience 2004; 124: 3–10, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Ma L, Liu Y, Ky B, Shughrue P J, Austin C P, Morris J A. Cloning and characterization of {DISC1}, the mouse ortholog of {DISC1} (Disrupted-in-Schizophrenia 1). Genomics 2002; 80: 662–72, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Austin C P, Ma L, Ky B, Morris J A, Shughrue P J. DISC1 (Disrupted in Schizophrenia-1) is expressed in limbic regions of the primate brain. Neuroreport 2003; 14: 951–4, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Miyoshi K, Honda A, Baba K, et al. Disrupted-in-Schizophrenia 1, a candidate gene for schizophrenia, participates in neurite outgrowth. Mol Psychiatry 2003; 8: 685–94, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Callicott J H, Straub R E, Pezawas L, et al. Variation in DISC1 affects hippocampal structure and function and increases risk for schizophrenia. Proc Nat Acad Sci U S A, (in press)[CSA]
- Angelucci F, Brene S, Mathe A A. BDNF in schizophrenia, depression and corresponding animal models. Mol Psychiatry, (in press)[CSA]
- Marin O, Rubenstein J L. Cell migration in the forebrain. Annu Rev Neurosci 2003; 26: 441–83, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Toyooka K, Asama K, Watanabe Y, et al. Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients. Psychiatry Res 2002; 110: 249–57, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Takahashi M, Shirakawa O, Toyooka K, et al. Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients. Mol Psychiatry 2000; 5: 293–300, [PUBMED], [INFOTRIEVE], [CSA]
- Dwivedi Y, Rizavi H S, Conley R R, Roberts R C, Tamminga C A, Pandey G N. Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. Arch Gen Psychiatry 2003; l6: 804–15, [CSA]
- Hattori M, Kunugi H, Akahane A, et al. Novel polymorphisms in the promoter region of the neurotrophin-3 gene and their associations with schizophrenia. Am J Med Genet 2002; 114: 304–9, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Jonsson E, Brene S, Zhang X R, et al Schizophrenia and neurotrophin-3 alleles. Acta Psychiatr Scand 1997; 95: 414–9, [PUBMED], [INFOTRIEVE], [CSA]
- Szekeres G, Juhasz A, Rimanoczy A, Keri S, Janka Z. The C270T polymorphism of the brain-derived neurotrophic factor gene is associated with schizophrenia. Schizophr Res 2003; 65: 15–8, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Neves-Pereira M, Cheung J K, Pasdar A, et al. BDNF gene is a risk factor for schizophrenia in a Scottish population. Mol Psychiatry 2005; 10: 208–12, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Skibinska M, Hauser J, Czerski P M, et al. Association analysis of brain-derived neurotrophic factor (BDNF) gene Val66Met polymorphism in schizophrenia and bipolar affective disorder. World J Biol Psychiatry 2004; 5: 215–20, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Egan M F, Kojima M, Callicott J H, et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003; 112: 257–69, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Fanous A H, Neale M C, Straub R C, et al. Clinical features of psychotic disorders and polymorphisms in HT2A, DRD2, DRD4, SLC6A3 (DAT1), and BDNF: a family based association study. Am J Med Genet B Neuropsychiatr Genet 2004; l125B: 69–78, [CROSSREF], [CSA]
- Krebs M O, Guillin O, Bourdell M C, et al. Brain derived neurotrophic factor ({BDNF}) gene variants association with age at onset and therapeutic response in schizophrenia. Mol Psychiatry 2000; 5: 558–62, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hong C J, Yu Y W, Lin C H, Tsai S J. An association study of a brain-derived neurotrophic factor Val66Met polymorphism and clozapine response of schizophrenic patients. Neurosci Lett 2003; 349: 206–8, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hariri A R, Goldberg T E, Mattay V S, et al. Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. J Neurosci 2003; 23: 6690–4, [PUBMED], [INFOTRIEVE], [CSA]
- Pezawas L, Verchinski B A, Mattay V S, et al. The brain-derived neurotrophic factor val66met polymorphism and variation in human cortical morphology. J Neurosci 2004; l24: 10099–102, [CROSSREF], [CSA]
- Shirts B H, Nimgaonkar V. The genes for schizophrenia: finally a breakthrough?. Curr Psychiatry Rep 2004; 6: 303–12, [PUBMED], [INFOTRIEVE], [CSA]
- Reiman E M, Caselli R J, Yun L S, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med 1996; 334: 752–8, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Small G W, Ercoli L M, Silverman D H, et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A 2000; 97: 6037–42, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Bookheimer S Y, Strojwas M H, Cohen M S, et al. Patterns of brain activation in people at risk for Alzheimer's disease. N Engl J Med 2000; 343: 450–6, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Petrella J R, Lustig C, Bucher L A, Jha A P, Doraiswamy P M. Prefrontal activation patterns in subjects at risk for Alzheimer disease. Am J Geriatr Psychiatry 2002; 10: 112–3, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Lesch K P, Bengel D, Heils A, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996; 274: 1527–31, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Caspi A, Sugden K, Moffitt T E, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003; 301: 386–9, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hariri A R, Mattay V S, Tessitore A, et al. Serotonin transporter genetic variation and the response of the human amygdala. Science 2002; 297: 400–3, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hariri A R, Drabant E M, Munoz K E, et al. A susceptibility gene for affective disorders and the response of the human amygdala. Arch Gen Psychiatry 2005; 62: 146–52, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- McGuffin P. Nature and nurture interplay: schizophrenia. Psychiatr Prax 2004; l31(suppl 2)S189–93, [CROSSREF], [CSA]